CYP51A1 and fungal infectious disease: Reported reasons for non-effective therapy and breakthrough invasive fungal infections are resistance due to mutations in CYP51, upregulation of CYP51 expression or upregulation of efflux pumps or, as a matter of debate, antifungal tolerance or host-specific insufficient bioavailability of the drug24,31,32.